💊 Purpose-built for GLP-1 & Telehealth Brands

Scan Your GLP-1 Marketing
Before the FDA Does

The FDA sent 30+ warning letters to telehealth brands in 2026. ScanCompliant automatically checks your GLP-1 website and ads for the exact violations they're citing — in under 15 minutes.

No credit card required
Results in 15 minutes
Full website scan, not just one page
⚠️ The FDA issued 30+ warning letters to GLP-1 and telehealth brands in the first half of 2026. The FTC launched a dedicated Healthcare Task Force in March. Read what they're citing →

Every GLP-1 Violation the FDA Is Citing — Checked Automatically

Our AI is trained on FDA warning letters, FTC enforcement actions, and FDCA requirements specific to compounded GLP-1 marketing.

🔄

Sameness & Equivalence Claims

Catches phrases like "same as Ozempic," "generic semaglutide," and "equivalent to Wegovy" — the #1 trigger in 2026 warning letters.

HIGH RISK
📊

Unsubstantiated Outcome Claims

Flags specific weight loss guarantees and "clinically proven" claims that aren't properly cited or don't reflect typical results.

HIGH RISK
🏛️

Implied FDA Approval

Detects language that implies your compounded GLP-1 is FDA-approved — including subtle phrasing like "FDA-compliant formula."

HIGH RISK
🩺

Disease Treatment Claims

Identifies diabetes, cardiovascular, and PCOS treatment claims made for compounded drugs that don't have approval for those indications.

HIGH RISK
📋

Missing or Buried Disclosures

Verifies that required disclosures (not FDA-approved, prescription required, results vary) appear near claims — not just in the footer.

MEDIUM RISK
💬

Non-Compliant Testimonials

Reviews testimonials for disease claims, missing "results not typical" disclaimers, and undisclosed compensation relationships.

MEDIUM RISK

False Urgency & Scarcity

Flags countdown timers and "limited supply" claims that can't be substantiated — a key FTC Healthcare Task Force target.

MEDIUM RISK
💰

Pricing & Subscription Claims

Checks for misleading price comparisons, unclear cancellation terms, and deceptive "free trial" framing that the FTC has cited.

MEDIUM RISK
🤖

Clara AI Explains Every Flag

Every finding includes the regulatory basis, the risk level, and a specific compliant alternative — not just a flag with no guidance.

AI-POWERED

From Website URL to Compliance Report in 3 Steps

No integrations, no setup. Enter your URL and ScanCompliant does the rest.

Enter Your URL

Paste your homepage, landing page, or a specific product page. ScanCompliant crawls and scans all content, including meta tags and image alt text.

AI Scans Every Claim

Clara AI reviews your copy against FDA drug marketing rules, FTC advertising standards, and compounded drug regulations specific to GLP-1s.

Get a Prioritized Report

Findings are sorted by risk level. Each flag includes the problematic text, why it's a risk, and exactly what to say instead.

The Exact Claims ScanCompliant Catches

These are real patterns from 2026 FDA warning letters. ScanCompliant flags all of them — and suggests compliant replacements.

Claim Found on Your Site Why It's Flagged Risk
"Same active ingredient as Ozempic® — lower cost" Sameness / equivalence claim. Compounded drugs are not equivalent to FDA-approved drugs. HIGH
"Lose 15% of your body weight — guaranteed" Specific outcome guarantee without substantiation that results are typical. HIGH
"FDA-compliant semaglutide formula" Implies FDA approval or endorsement of compounded product. HIGH
"Manage type 2 diabetes with GLP-1" Disease treatment claim for a compounded drug not approved for diabetes. HIGH
"My A1C dropped from 9.1 to 5.4!" — Sarah M. Testimonial contains a disease claim (A1C change). No "results not typical" disclosure. HIGH
Not-FDA-approved disclosure only appears in footer Disclosure must appear near claims — not 2,000px below the CTA where most users never scroll. MED
"Prescription-grade GLP-1 at $299/month" "Prescription-grade" implies a regulatory quality standard that doesn't exist for compounded drugs. MED
Disclosure appears near claims + "results vary" on all testimonials No issues found. PASS

One Warning Letter Costs More Than a Year of Pro

Responding to an FDA warning letter typically costs $50,000–$200,000 in legal fees. ScanCompliant Pro is $149/month.

ScanCompliant Pro
$149
/ month
or $99/month billed annually — cancel anytime
  • Unlimited website scans
  • GLP-1 / telehealth-specific violation detection
  • Clara AI explanation for every finding
  • Compliant rewrites suggested for flagged claims
  • Scan landing pages, ads, and email copy
  • Priority support
  • 5-day free trial — no credit card required
Start Free Trial →
⚠️ The math: ScanCompliant Pro at $149/month = $1,788/year. One FDA warning letter response = $50,000–$200,000 in legal fees. One prevented action covers 28–112 years of Pro subscription.

Telehealth Teams Trust ScanCompliant

Brands using ScanCompliant caught high-risk claims before they went live — and before regulators noticed.

★★★★★

"We launched a new GLP-1 landing page and ran it through ScanCompliant before going live. It caught three sameness claims our copywriter had added without realizing the risk. Would have been a major problem."

J
Jason K.
Head of Marketing, Telehealth Brand
★★★★★

"Our previous compliance review was a manual checklist that our legal team ran quarterly. ScanCompliant does the same thing in 15 minutes and catches things the checklist missed — like implied FDA approval in image alt text."

R
Rachel M.
VP Operations, GLP-1 Program
★★★★★

"The Clara AI explanations are what I actually needed. Not just a flag — but an explanation of the regulatory basis and a specific compliant alternative. Our team learned from every report."

A
Amira D.
Regulatory Affairs Lead

Common Questions

Yes. ScanCompliant's GLP-1 checks are specifically trained on the violations the FDA has cited in 2025–2026 warning letters targeting compounded GLP-1 programs — including sameness claims, missing compounding disclosures, and implied FDA approval for compounded drugs.
Yes. You can scan any URL — your homepage, individual product landing pages, blog posts, or even a paste of email or ad copy. The tool reviews all text content on the page, including meta descriptions and image alt text.
ScanCompliant is a screening tool, not legal advice. A lawyer provides authoritative legal counsel and can represent you in enforcement proceedings. ScanCompliant helps you catch likely issues before they go live — faster, more frequently, and at a fraction of the cost of attorney review. Most teams use both: ScanCompliant for routine screening, legal counsel for complex questions and high-stakes decisions.
Our violation library is updated on a rolling basis as new FDA warning letters and FTC enforcement actions are published. GLP-1-specific patterns were last updated in July 2026. You can check the update log in your dashboard.
Yes. The scan covers both FDA drug marketing requirements and FTC advertising standards, including the updated 2023 endorsement guidelines (which affect testimonials and influencer content), and the FTC's specific focus areas in the 2026 Healthcare Task Force mandate.
Yes. Clara AI is available inside the dashboard to answer specific questions about claim language — you can paste a phrase and ask whether it's likely to be flagged and why. It's like having a compliance-trained reviewer available 24/7 for quick questions.

Your Next Landing Page Could Be
Someone's Warning Letter Exhibit

Get 5 days of full access. Scan your GLP-1 marketing and see every flag before your next launch.

Start Free Trial — No Credit Card
5-day free trial
Results in 15 minutes
Cancel anytime

Looking for more detail on what the FDA is citing? Read our GLP-1 marketing compliance guide →